Step 4 — Our current treks
Making genomic test results actionable
Elevation Oncology applies all of its insights towards the development of targeted therapies for novel driver alterations with high unmet patient needs.
Our first summit: NRG1 fusions
Our first clinical trial, CRESTONE (pronounced CRESS-tone), is a Phase 2 study of seribantumab in cancer patients with a solid tumor of any origin that expresses a genomic change called an NRG1 fusion. The CRESTONE study is actively enrolling patients now.LEARN MORE ABOUT Crestone